Damian deGoa

Mr. deGoa served as the COO of OA Private Capital, a family office investment firm focused on private equity investments from 2022 to 2024 and was CEO of Liquidia Corporation from December 2020 to January 2022, having previously served as CEO of RareGen, LLC, a rare disease commercial company that merged with Liquidia in 2020. Mr. deGoa was also CEO of Breas Medical Group, a global respiratory medical device company, headquartered in Sweden, until its sale to Fosun Pharma. In addition, he served as Managing Director/Partner at PBM Capital Group, a healthcare investment firm where he was responsible for M&A and executive leadership at portfolio companies like RareGen and Breas. Mr. deGoa started his career in the healthcare industry with Perrigo Company holding various roles including corporate development, international business development, and divisional finance lead. Mr. deGoa holds a BA from the University of Michigan and an MBA from Depaul University.